VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1

HY Ren, DE Grove, O De La Rosa… - Molecular biology of …, 2013 - Am Soc Cell Biol
HY Ren, DE Grove, O De La Rosa, SA Houck, P Sopha, F Van Goor, BJ Hoffman, DM Cyr
Molecular biology of the cell, 2013Am Soc Cell Biol
Cystic fibrosis (CF) is a fatal genetic disorder associated with defective hydration of lung
airways due to the loss of chloride transport through the CF transmembrane conductance
regulator protein (CFTR). CFTR contains two membrane-spanning domains (MSDs), two
nucleotide-binding domains (NBDs), and a regulatory domain, and its channel assembly
requires multiple interdomain contacts. The most common CF-causing mutation, F508del,
occurs in NBD1 and results in misfolding and premature degradation of F508del-CFTR. VX …
Cystic fibrosis (CF) is a fatal genetic disorder associated with defective hydration of lung airways due to the loss of chloride transport through the CF transmembrane conductance regulator protein (CFTR). CFTR contains two membrane-spanning domains (MSDs), two nucleotide-binding domains (NBDs), and a regulatory domain, and its channel assembly requires multiple interdomain contacts. The most common CF-causing mutation, F508del, occurs in NBD1 and results in misfolding and premature degradation of F508del-CFTR. VX-809 is an investigational CFTR corrector that partially restores CFTR function in people who are homozygous for F508del-CFTR. To identify the folding defect(s) in F508del-CFTR that must be repaired to treat CF, we explored the mechanism of VX-809 action. VX-809 stabilized an N-terminal domain in CFTR that contains only MSD1 and efficaciously restored function to CFTR forms that have missense mutations in MSD1. The action of VX-809 on MSD1 appears to suppress folding defects in F508del-CFTR by enhancing interactions among the NBD1, MSD1, and MSD2 domains. The ability of VX-809 to correct F508del-CFTR is enhanced when combined with mutations that improve F508del-NBD1 interaction with MSD2. These data suggest that the use of VX-809 in combination with an additional CFTR corrector that suppresses folding defects downstream of MSD1 may further enhance CFTR function in people with F508del-CFTR.
Am Soc Cell Biol